Summary:
- The U.S. Food and Drug Administration (FDA) has released draft guidance on the regulation of products containing cannabinoids derived from hemp.
- The guidance outlines the FDA's current thinking on the regulation of hemp-derived cannabinoids, including CBD, and provides clarity on the agency's approach to these products.
- The draft guidance addresses issues such as the legal status of hemp-derived cannabinoids, the FDA's regulatory authority, and the agency's concerns about the safety and quality of these products.